Diana Douglas focuses her practice on corporate, securities and transactional matters. Diana advises clients on public company reporting and disclosure compliance, public and private offerings of equity and debt securities, mergers and acquisitions, corporate restructurings and commercial transactions. She also counsels clients on general corporate and corporate governance matters.

Show More

• Represented Indaptus Therapeutics, Inc. (NASDAQ: INDP) in a business combination with Decoy Biosystems, Inc., which involved a series of complex corporate and securities transactions, including the registration of domestication merger and reverse merger shares on a Form S-4, an initial listing with Nasdaq for Indaptus, a delisting of Indaptus’ predecessor company from Nasdaq, a class action lawsuit, the establishment of a new equity incentive plan and filing of a Form S-8, a reverse share split and the registration of private investment in public equity (PIPE) shares on a Form S-1
• Represented Constellation Brands, Inc. (NYSE: STZ) in its $1 billion public offering of 2.250% senior notes due 2031
• Represented Healthcare Trust of America, Inc. (NYSE: HTA) in its at-the-market program for the sale of up to $750 million of Class A common stock

Show More

Education
Santa Clara University School of Law, JD, 2015
University of California – Los Angeles, BA, 2009

Admissions
California